Lovotibeglogene autotemcel (Lyfgenia) gene therapy coverage
Customize your policy alerts
Sign up for meridian Policy MDN.CP.PHAR.627 alerts
Get alerted when Policy MDN.CP.PHAR.627 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity, authorization, and coverage criteria for Lyfgenia (lovotibeglogene autotemcel) for members (Medicaid line of business) including initial and continuation criteria and documentation requirements for providers.
No material clinical or coverage changes in this revision.
Coverage Criteria for Lyfgenia (lovotibeglogene autotemcel)
Initial Therapy - Sickle Cell Disease
Covered when ALL of the following are met for SCD:
Initial therapy requirements
Initial coverage for SCD requires meeting all specified clinical and laboratory criteria.
Initial therapy (SCD dosing)
Dosing guidance provided for sickle cell disease
Appendix E specifies this as the minimum recommended dose for SCD.
Appendix E: Safety and Product Parameters
Safety-related conditions and dosing/product parameters included in appendices:
These are examples of advanced liver disease noted in Appendix E; may inform eligibility or risk assessment.
Listed as SCD minimum recommended dose in Appendix E.
Product concentration and packaging details from Appendix E.
Coverage is not authorized for indications that are not FDA‑approved and are not specifically addressed by this policy unless the provider supplies sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policies (for Medicaid, see CP.PMN.53) or the applicable evidence of coverage documents.
The policy identifies examples of advanced liver disease to inform eligibility and risk assessment. Examples include, but are not limited to: cirrhosis; bridging or significant fibrosis; active hepatitis; persistent AST, ALT, or direct bilirubin values > 3x ULN; and baseline prothrombin time (PT) or partial thromboplastin time (PTT) > 1.5x ULN.
Referenced diagnosis and procedure codes in this clinical policy are provided for informational purposes only; inclusion of a code does not guarantee coverage. Providers should verify current coding guidance and submit prior authorization requests and claims consistent with applicable billing rules and payer requirements.
Initial Therapy Criteria
Initial therapy requirements
Initial coverage for SCD requires meeting all specified clinical and laboratory criteria.
Initial therapy (SCD dosing)
Dosing guidance provided for sickle cell disease
Continuation Therapy
Continuation Therapy
Lyfgenia is a single-administration gene therapy; ongoing maintenance dosing is not applicable.
Approval duration: Not applicable
Continuation
Coding and Product Parameters
| J3394 | Injection, lovotibeglogene autotemcel, per treatment |
Provider Actions, Authorization, and Documentation
Prior authorization requires PDAC UM review
Prior authorization for lovotibeglogene autotemcel (Lyfgenia) requires submission of clinical documentation and will be reviewed by the Precision Drug Action Committee (PDAC) Utilization Management process; providers must include documentation that all approval criteria are met.
- Submit office chart notes, lab results, and other clinical information demonstrating the member meets all approval criteria.
- Refer to CC.PHAR.21 for PDAC process details.
PDAC Utilization Management review required
All requests under this policy require PDAC Utilization Management Review; lack of PDAC approval may result in denial of the request.
- PDAC review is mandatory for requests reviewed under this policy.
Billing code: use HCPCS J3394
Claims and prior authorization submissions should reference HCPCS code J3394 (Injection, lovotibeglogene autotemcel, per treatment); inclusion of the code is informational and does not by itself guarantee coverage.
- Use HCPCS J3394 when submitting claims for lovotibeglogene autotemcel.
- Coding inclusion is informational—prior authorization and PDAC approval are still required.
Consider listed therapeutic alternatives (e.g., hydroxyurea, Siklos)
Therapeutic alternatives such as hydroxyurea and Siklos are listed in Appendix B and should be considered as part of the standard-of-care assessment prior to gene therapy.
- Document prior use, failure, or intolerance to hydroxyurea if applicable.
- Appendix B lists dosing regimens for hydroxyurea and Siklos as alternatives.
No step therapy requirements specified
This policy does not describe any step therapy requirements; no mandated step therapy is specified in the cited sections.
- Documented failure or intolerance to hydroxyurea is an approval criterion but is not presented here as a formal step therapy protocol.
Submit supporting clinical documentation with request
Providers must submit supporting documentation (office chart notes, lab results, or other clinical information) showing the member meets all approval criteria when requesting authorization.
- Include clinical notes, laboratory data, genetic test results, and prescriber attestations as applicable.
Genetic testing and prescriber attestation required
Include genetic testing confirming sickle cell disease (e.g., confirmed βS/βS genotype per Appendix D) and a prescriber attestation that the patient is clinically stable and eligible for HSCT and has prior treatment history (e.g., hydroxyurea failure/intolerance).
- Provide genetic confirmation showing βS/βS genotype as applicable.
- Prescriber must attest to HSCT eligibility and document hydroxyurea failure or intolerance if claimed.
Reference prescribing information and cited literature
Providers should reference and attach current Lyfgenia prescribing information and relevant cited literature (Appendix E references the Lyfgenia PI and key clinical studies) when documenting requests.
- Include Lyfgenia Prescribing Information and pertinent clinical references cited in Appendix E as supporting documentation.
Non‑FDA indications require off‑label documentation
Coverage is not authorized for non‑FDA approved indications unless sufficient documentation per the off‑label use policies is provided; requests for non‑FDA indications without required off‑label documentation may be denied.
- Follow off‑label use policy CP.PMN.53 (Medicaid) or other applicable off‑label policy and provide supporting evidence.
Coding inclusion does not guarantee coverage
Inclusion or exclusion of any codes in this clinical policy does not guarantee coverage; providers must reference the most up-to-date professional coding guidance prior to claim submission.
- Coding listed in the policy is informational only and does not substitute for prior authorization or PDAC approval.
Step Therapy Requirements
| Step | Requirement |
|---|---|
| 1 | Documented failure or intolerance to hydroxyurea at any point in the past (per clinician judgement). |
Quantity Limits and Product Presentation
Site of Care and Provider Qualifications
Prescriber must be hematologist or transplant specialist
Medication must be prescribed by or in consultation with a board‑certified hematologist or transplant specialist experienced in SCD; Lyfgenia is an HSCT‑based gene therapy typically administered in specialized transplant centers or hospital outpatient settings.
- Ensure prescriber specialty and site-of-care capabilities are documented for the authorization request.
Product is single‑dose suspension in 1–4 infusion bags
Lyfgenia is supplied as a single‑dose cell suspension in one to four infusion bags (1.7 to 20 × 10^6 cells/mL) in cryopreservation solution; site-of-care planning must account for cryopreserved cell handling and specialized infusion capabilities.
- Document facility capability for cryopreserved cell thawing, handling, and IV infusion.
Background
Lovotibeglogene autotemcel (Lyfgenia) is an autologous hematopoietic stem cell‑based gene therapy supplied as a single‑dose cell suspension (one to four infusion bags) intended for the treatment of patients with sickle cell disease. The product and appendices note dosing and safety parameters relevant to use, including minimum dose and product concentration ranges; clinicians should review the full prescribing information and product appendices when considering therapy.
Definitions
Coding Notes and References
| J3394 | Injection, lovotibeglogene autotemcel, per treatment |
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.